Listen
ARIXTRA
-
Opinions on drugs -
Posted on
Jun 22 2011
- Updated on
Jul 26 2011
Reason for request
Inclusion on the list of medicines refundable by National Health Insurance (B/2 and B/7) and approved for hospital use (B/10) in the extension of indication: "Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis".
-
Clinical Benefit
| Moderate |
The actual benefit of ARIXTRA 2.5 mg is moderate. |
Clinical Added Value
| no clinical added value |
The Committee considers that ARIXTRA 2.5 mg does not contribute any improvement in actual benefit (level V) in the treatment strategy in view of the uncertainty regarding the clinical benefit of a 45-day treatment period in the very varied population of patients with isolated SVT. |
English version
Contact Us
Évaluation des médicaments
